Capital Fund Management (CFM)’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.34M | Buy |
91,987
+43,903
| +91% | +$1.6M | 0.01% | 512 |
|
|
2025
Q1 | $1.74M | Buy |
48,084
+13,859
| +40% | +$502K | 0.01% | 573 |
|
|
2024
Q4 | $1.44M | Sell |
34,225
-2,286
| -6% | -$96.2K | ﹤0.01% | 630 |
|
|
2024
Q3 | $2.03M | Buy |
36,511
+21,515
| +143% | +$1.2M | 0.01% | 510 |
|
|
2024
Q2 | $616K | Buy |
+14,996
| New | +$616K | ﹤0.01% | 597 |
|
|
2023
Q2 | – | Sell |
-14,398
| Closed | -$577K | – | 890 |
|
|
2023
Q1 | $577K | Buy |
14,398
+1,081
| +8% | +$43.3K | ﹤0.01% | 493 |
|
|
2022
Q4 | $617K | Sell |
13,317
-37,649
| -74% | -$1.74M | ﹤0.01% | 475 |
|
|
2022
Q3 | $2.11M | Buy |
+50,966
| New | +$2.11M | 0.02% | 313 |
|
|
2017
Q3 | – | Sell |
-40,800
| Closed | -$2.53M | – | 1012 |
|
|
2017
Q2 | $2.53M | Buy |
+40,800
| New | +$2.53M | 0.02% | 372 |
|
|
2016
Q2 | – | Sell |
-4,277
| Closed | -$271K | – | 1054 |
|
|
2016
Q1 | $271K | Buy |
+4,277
| New | +$271K | ﹤0.01% | 755 |
|